Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

By afschroeder • June 21, 2025

Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriseti S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. 2025 Jun 19:S2588-9311(25)00169-5. doi: 10.1016/j.euo.2025.05.027. Epub ahead of print. PMID: 40541485.

Tags: Abiraterone acetate, Androgen annihilation therapy, Apalutamide, Cardiology/Epi, Castrate-sensitive prostate cancer, Hematology/Oncology, Leuprolide, Metastasis-directed therapy, Oligorecurrence, prostate cancer, Publications, Stereotactic body radiotherapy, Veterans Administration

Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy

Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]

Towards accurate interpretation of hypothesis testing in cardiology randomised controlled clinical trials

Sharifan A, Fonarow G. Towards accurate interpretation of hypothesis testing in cardiology randomised controlled clinical trials. Heart. 2025 Jun 20:heartjnl-2025-326515. doi: 10.1136/heartjnl-2025-326515. Epub ahead of[...]

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats[...]